Home  »  Science   »  What To Expect As Reata Pharmaceuticals Inc. (NASD...

What To Expect As Reata Pharmaceuticals Inc. (NASDAQ: RETA) Delivers An 34.56% Gain In 6 Months

During the last session, Reata Pharmaceuticals Inc. (NASDAQ:RETA)’s traded shares were 0.48 million, with the beta value of the company hitting 1.10. At the end of the trading day, the stock’s price was $35.70, reflecting an intraday gain of 1.05% or $0.37. The 52-week high for the RETA share is $131.51, that puts it down -268.38 from that peak though still a striking 43.31% gain since the share price plummeted to a 52-week low of $20.24. The company’s market capitalization is $1.29B, and the average intraday trading volume over the past 10 days was 0.27 million shares, and the average trade volume was 409.61K shares over the past three months.

Reata Pharmaceuticals Inc. (RETA) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.80. RETA has a Sell rating from 0 analyst(s) out of 8 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 1 suggest Overweight, and 6 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$2.02.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

Reata Pharmaceuticals Inc. (NASDAQ:RETA) trade information

Reata Pharmaceuticals Inc. (RETA) registered a 1.05% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.05% in intraday trading to $35.70 this Friday, 08/05/22, hitting a weekly high. The stock’s 5-day price performance is 16.36%, and it has moved by -0.83% in 30 days. Based on these gigs, the overall price performance for the year is -71.71%. The short interest in Reata Pharmaceuticals Inc. (NASDAQ:RETA) is 5.03 million shares and it means that shorts have 13.76 day(s) to cover.

The consensus price target of analysts on Wall Street is $59.63, which implies an increase of 40.13% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $35.00 and $75.00 respectively. As a result, RETA is trading at a discount of -110.08% off the target high and 1.96% off the low.

Reata Pharmaceuticals Inc. (RETA) estimates and forecasts

Statistics show that Reata Pharmaceuticals Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Reata Pharmaceuticals Inc. (RETA) shares have gone up 34.56% during the last six months, with a year-to-date growth rate less than the industry average at -1.83% against 1.00. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to shrink -1.00% this quarter and then drop -10.20% in the quarter after that. In the rating firms’ projections, revenue will decrease -53.80% compared to the previous financial year.

Revenue for the current quarter is expected to be $1.46 million as predicted by 7 analyst(s). Meanwhile, a consensus of 7 analyst(s) estimates revenue growth to $1.13 million by the end of Sep 2022.

While earnings are projected to return -2.20% in 2022.

RETA Dividends

Reata Pharmaceuticals Inc. is due to release its next quarterly earnings between February 28 and March 04. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Reata Pharmaceuticals Inc. (NASDAQ:RETA)’s Major holders

Reata Pharmaceuticals Inc. insiders own 4.07% of total outstanding shares while institutional holders control 87.73%, with the float percentage being 91.45%. Wellington Management Group, LLP is the largest shareholder of the company, while 220 institutions own stock in it. As of Mar 30, 2022, the company held over 4.4 million shares (or 13.94% of all shares), a total value of $144.03 million in shares.

The next largest institutional holding, with 2.9 million shares, is of CPMG INC’s that is approximately 9.18% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $94.9 million.

Also, the Mutual Funds coming in first place with the largest holdings of Reata Pharmaceuticals Inc. (RETA) shares are Hartford Mid Cap Fund and Vanguard Specialized-Health Care Fund. Data provided on Apr 29, 2022 indicates that Hartford Mid Cap Fund owns about 1.58 million shares. This amounts to just over 5.02 percent of the company’s overall shares, with a $40.19 million market value. The same data shows that the other fund manager holds slightly less at 1.24 million, or about 3.92% of the stock, which is worth about $31.4 million.

Leave a Comment

Your email address will not be published.

On Key

Related Posts

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]